Equities
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Fresenius Medical Care AG, formerly Fresenius Medical Care AG & Co. KGaA is a Germany-based Company, which is a kidney dialysis institute. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD), as well as other healthcare services. The Company also develops and manufactures a wide variety of health care products, which includes dialysis and non-dialysis products. Its dialysis products include hemodialysis machines, peritoneal cyclers, dialyzers, peritoneal solutions and granulates, bloodlines, renal pharmaceuticals and systems for water treatment. Its non-dialysis products include acute cardiopulmonary and apheresis products. The Company supplies dialysis clinics it owns, operates or manages with a broad range of products, and sells dialysis products to other dialysis service providers.

  • Revenue in USD (TTM)20.28bn
  • Net income in USD694.72m
  • Incorporated2006
  • Employees113.08k
More ▼

Institutional shareholders

5.13%Per cent of shares held by top holders
HolderShares% Held
Pzena Investment Management LLCas of 30 Sep 202416.22m2.76%
Fiduciary Management, Inc.as of 30 Sep 20246.56m1.12%
Dodge & Coxas of 30 Sep 20244.17m0.71%
Parametric Portfolio Associates LLCas of 30 Sep 2024921.52k0.16%
Aperio Group LLCas of 30 Sep 2024476.09k0.08%
Goldman Sachs Asset Management LPas of 30 Sep 2024453.80k0.08%
Integral Health Asset Management LLCas of 30 Sep 2024450.00k0.08%
Envestnet Asset Management, Inc.as of 30 Sep 2024333.78k0.06%
Arrowstreet Capital LPas of 30 Sep 2024279.29k0.05%
Northern Trust Investments, Inc.(Investment Management)as of 30 Sep 2024248.24k0.04%
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.